Merck agrees to sell CDMO business to Lonza

Bitget2026/11/03 06:50

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Merck agreed to sell its Life Science contract development and manufacturing business to Lonza for a mid-triple-digit million-euro amount.
Closing is expected in mid-2027, with the acquisition expanding Lonza’s US manufacturing capacity.
The sale sharpens the Life Science portfolio’s focus on innovation-driven businesses with strong value-creation potential.
BioReliance Contract Testing Services is excluded from the transaction and will remain within Life Science.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Merck agrees to sell CDMO business to Lonza

You may also like

Crypto prices